Among the items addressed by Valeant Pharmaceuticals International on Monday to tackle the thorny accounting issues surrounding the company was the firm’s relationship with one of its distributors.

Source: Valeant’s newest disclosure — the $100 million option to buy a company for nothing – MarketWatch